ResMed Sells MatrixCare to Frazier for $490M, a $260M Loss on 2018 Price
The sleep-apnea device maker divests the software unit for 35% less than its $750M acquisition cost, signaling a retreat from non-core assets despite the unit's profitability.
Read the full articleYou might also wanna read
Resmed to sell software business MatrixCare to private equity firm
Selling the unit, which provides an EHR for post-acute care, will allow the respiratory device maker to shift more resources to faster-growi
ResMed to sell MatrixCare business to Frazier Healthcare, terms undisclosed
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
Capricorn Fund Managers Ltd Acquires Significant Stake in SkinHealth Systems Inc
Related Stocks: SKIN , AXGN , BAC , KKR , CVNA , ZYME
Clover Health's CEO Sold Company Shares Worth $1.7 Million. Here's What That Means for Investors.
This Medicare Advantage insurer leverages proprietary technology to manage care costs. A key insider recently trimmed their stake.
Nurix Therapeutics, Inc. (NRIX) reports Q2 loss, lags revenue estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.73. Th
ResMed Inc (NYSE:RMD) Builds on a Quality Foundation with Strong Profitability and Cash Conversion
Explore ResMed (RMD) as a quality investment with 68.2% ROIC, 92% cash conversion, low leverage, and 15.82% EBIT growth, scoring 8/10 in fun
Comments
Sign in to join the conversation.
No comments yet. Be the first.